Physician profile
Kevin Eugene Boucher
NPI 1992869523
$4,858.71
in general payments reported to CMS, 2019-2025
25 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $859 · 2021: $719 · 2022: $618 · 2023: $554 · 2024: $699 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,177.96 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $572.48 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $490.31 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.64 | 2019-2025 | Jardiance, Tradjenta |
| Pfizer INC. | $332.36 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $254.81 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $251.41 | 2019-2023 | Belsomra |
| Glaxosmithkline, LLC. | $196.37 | 2019-2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $171.75 | 2020-2024 | Eliquis, Camzyos |
| Allergan, INC. | $171.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.98 | 2020-2023 | Xifaxan, Trulance |
| Corcept Therapeutics | $106.03 | 2024 | Korlym |
| Exact Sciences Corporation | $102.48 | 2025 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $93.24 | 2021-2022 | |
| Astellas Pharma US INC | $87.04 | 2019-2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $68.12 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $40.73 | 2024-2025 | Rexulti, Jynarque |
| Amarin Pharma, INC. | $32.61 | 2019 | |
| Seqirus USA INC | $25.84 | 2019 | |
| Sanofi Pasteur INC. | $24.69 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $22.93 | 2025 | Uptravi, Opsumit |
| Abbvie INC. | $21.75 | 2022 | |
| Lundbeck LLC | $19.75 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.41 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $15.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Boucher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.